ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬の世界市場レポート 2025年

ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で68億9,000万米ドルに成長します。予測期間中の成長は、発展途上国におけるヘルスケアインフラの拡大、がん予防に対する政府の取り組み、研究開発資金の増加、免疫不全状態の罹患率の増加、世界の医療費の増加などの要因によるものと考えられます。予測期間における主な動向としては、治療用ワクチン開発の進展、新規抗ウイルス剤の創出、診断における人工知能の統合、免疫療法アプローチの出現、CRISPRおよび遺伝子編集技術の活用などが挙げられます。

子宮頸がんの有病率の増加は、ヒトパピローマウイルス（HPV）およびサイトメガロウイルス（CMV）治療市場の成長を促進すると予想されます。子宮頸がんは、子宮頸部（子宮の下部で膣につながる部分）に発生する悪性腫瘍であり、主にHPVの高リスク株への持続的感染が原因で増加しています。これらの感染は子宮頸部細胞に異常な変化を引き起こし、早期に発見して治療しなければがんに発展する可能性があります。HPVおよびCMV治療薬は、子宮頸がんの管理において、ウイルスに起因する疾患の進行を標的とし、患者の転帰を改善することにより、重要な役割を果たしています。長期的な健康と生活の質を高める抗ウイルス治療と免疫療法を提供することで、がんのリスクを低減するのに役立っています。例えば、2024年4月に米国がん協会が発表した報告書によると、2022年に世界で新たに子宮頸がんと診断された患者は約2,000万人であり、2050年にはこの数が3,500万人に増加するとの予測が出ています。このような子宮頸がんの有病率の増加が、HPVおよびCMV治療市場の成長を促進しています。

HPVおよびCMV治療薬市場の主要企業は、アンメット・メディカル・ニーズに対応し、治療効果を高め、既存治療に対する耐性を低下させ、免疫不全患者の転帰を改善するために、移植後抗サイトメガロウイルス（CMV）治療などの革新的ソリューションの開発に注力しています。移植後の抗CMV治療は、免疫抑制により高いリスクを抱える臓器移植や幹細胞移植のレシピエントにおけるCMV感染の予防や管理を目的としています。例えば、日本に拠点を置く武田薬品工業株式会社は2024年6月、現行の抗CMV薬に耐性を示す移植後CMV感染症または疾患の治療薬として、リブテンシティ（一般名：マリバビル）について厚生労働省から承認を取得しました。本剤は、サイトメガロウイルス（CMV）に特異的なUL97プロテインキナーゼを特異的に標的として阻害する国内唯一の治療薬であり、従来の治療薬とは異なる新たな作用機序を有する画期的な抗ウイルス剤です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：成長率分析
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場の実績：規模と成長、2019～2024年
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：治療の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• ワクチン
• 抗ウイルス薬
• 免疫療法
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 筋肉内
• 経口
• 局所
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 子宮頸がん
• 性器イボ
• 頭頸部がん
• 肛門がん
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 小売薬局
• オンライン薬局
• 専門クリニック
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：ワクチンの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 予防ワクチン
• 治療ワクチン
• 組み換えワクチン
• 生弱毒化ワクチン
• ウイルス様粒子（VLP）ベースのワクチン
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：抗ウイルス薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• ヌクレオシド類似体
• 非ヌクレオシド系逆転写酵素阻害剤（NNRTI）
• プロテアーゼ阻害剤
• デオキシリボ核酸ポリメラーゼ阻害剤
• ヘリカーゼ-プライマーゼ阻害剤
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：免疫療法の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 免疫チェックポイント阻害剤
• 治療用サイトカイン
• 養子T細胞療法

第7章 地域別・国別分析

• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：競合情勢
• ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline（GSK）plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Cepheid Inc.
• QIAGEN N.V.
• Vir Biotechnology Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場、2029年：新たな機会を提供する国
• ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場、2029年：新たな機会を提供するセグメント
• ヒトパピローマウイルス（HPV）サイトメガロウイルス（CMV）治療薬市場、2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics refer to medical treatments aimed at managing, reducing, or eliminating infections caused by HPV and CMV. These treatments focus on controlling viral replication, preventing disease progression, and alleviating symptoms associated with conditions such as cervical cancer (HPV) and congenital infections or complications in immunocompromised individuals (CMV).

The main therapeutic types in the HPV and CMV therapeutics market include vaccines, antiviral drugs, and immunotherapy. Vaccines are biological formulations designed to induce immunity against specific infectious diseases. These vaccines are administered through various routes, including intramuscular, oral, and topical. The primary indications for these treatments include cervical cancer, genital warts, head and neck cancer, and anal cancer. Distribution channels for these therapeutics include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market statistics, including human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic industry global market size, regional shares, competitors with an human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market share, detailed human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic industry. The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market size has grown strongly in recent years. It will grow from $4.55 billion in 2024 to $4.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to factors such as the increasing prevalence of human papillomavirus (HPV) and cytomegalovirus (CMV) infections, growing awareness of sexually transmitted infections, the development of antiviral drugs and vaccines, the rising incidence of HPV-related cancers, and public health vaccination initiatives.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market size is expected to see strong growth in the next few years. It will grow to $6.89 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as the expansion of healthcare infrastructure in developing countries, government initiatives for cancer prevention, increased funding for research and development, the growing incidence of immunocompromised conditions, and rising healthcare expenditure worldwide. Key trends in the forecast period include advancements in therapeutic vaccine development, the creation of novel antiviral agents, the integration of artificial intelligence in diagnostics, the emergence of immunotherapy approaches, and the utilization of CRISPR and gene-editing technologies.

The increasing prevalence of cervical cancer is expected to drive the growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market. Cervical cancer, a malignant tumor that develops in the cervix, the lower part of the uterus that connects to the vagina, is primarily rising due to persistent infections with high-risk strains of HPV. These infections cause abnormal changes in cervical cells that can develop into cancer if not detected and treated early. HPV and CMV therapeutics play a vital role in managing cervical cancer by targeting the virus-driven disease progression and improving patient outcomes. They help reduce the risk of cancer by providing antiviral treatments and immunotherapies that enhance long-term health and quality of life. For example, a report by the American Cancer Society in April 2024 revealed that approximately 20 million new cervical cancer cases were diagnosed globally in 2022, with projections showing this number could rise to 35 million by 2050. This increasing prevalence of cervical cancer is propelling the growth of the HPV and CMV therapeutic market.

Leading companies in the HPV and CMV therapeutics market are focusing on the development of innovative solutions, such as post-transplant anti-cytomegalovirus (CMV) treatments, to address unmet medical needs, enhance treatment efficacy, reduce resistance to existing therapies, and improve outcomes for immunocompromised patients. Post-transplant anti-CMV treatments are designed to prevent or manage CMV infections in organ or stem cell transplant recipients who are at high risk due to immunosuppression. For instance, in June 2024, Takeda Pharmaceutical Company Limited, based in Japan, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LIVTENCITY (maribavir) to treat post-transplant CMV infections or diseases that are resistant to current anti-CMV medications. This innovative antiviral agent is the only treatment in Japan that specifically targets and inhibits the cytomegalovirus (CMV)-specific UL97 protein kinase, offering a new mechanism of action distinct from traditional therapies.

In May 2022, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, acquired the rights to Valcyte from F. Hoffmann-La Roche AG. With this acquisition, Cheplapharm aims to expand its antiviral portfolio by adding Valcyte, a drug primarily used to treat cytomegalovirus (CMV) infections in transplant patients. F. Hoffmann-La Roche AG, a healthcare and pharmaceutical company based in Switzerland, specializes in developing and marketing Valcyte for CMV infections.

Major players in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline (GSK) plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Cepheid Inc., QIAGEN N.V., Vir Biotechnology Inc., Meridian Bioscience Inc.

North America was the largest region in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market consists of revenues earned by entities providing specific services such as antiviral drug infusion and dispensing, therapeutic vaccine administration, genotypic resistance testing, viral load monitoring, patient counselling and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market also includes sales of antiviral medications, therapeutic vaccines targeting human papillomavirus strains, immunomodulators, monoclonal antibodies, and gene therapy-based treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Types: Vaccines; Antiviral Drugs; Immunotherapy
• 2) By Route of Administration: Intramuscular; Oral; Topical
• 3) By Indications: Cervical Cancer; Genital Warts; Head And Neck Cancer; Anal Cancer
• 4) By Distribution Channel: Hospitals; Retail Pharmacies; Online Pharmacies; Specialty Clinics
• Subsegments:
• 1) By Vaccines: Prophylactic Vaccines; Therapeutic Vaccines; Recombinant Vaccines; Live Attenuated Vaccines; Virus-Like Particle (VLP) Based Vaccines
• 2) By Antiviral Drugs: Nucleoside Analogues; Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); Protease Inhibitors; Deoxyribonucleic Acid Polymerase Inhibitors; Helicase-Primase Inhibitors
• 3) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Therapeutic Cytokines; Adoptive T-cell Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Characteristics

3. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Trends And Strategies

4. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Growth Rate Analysis
• 5.4. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Total Addressable Market (TAM)

6. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Segmentation

• 6.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Antiviral Drugs
• Immunotherapy
• 6.2. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular
• Oral
• Topical
• 6.3. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Cancer
• Genital Warts
• Head And Neck Cancer
• Anal Cancer
• 6.4. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• 6.5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prophylactic Vaccines
• Therapeutic Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines
• Virus-Like Particle (VLP) Based Vaccines
• 6.6. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogues
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Protease Inhibitors
• Deoxyribonucleic Acid Polymerase Inhibitors
• Helicase-Primase Inhibitors
• 6.7. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Therapeutic Cytokines
• Adoptive T-cell Therapy

7. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Regional And Country Analysis

• 7.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 8.1. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 9.1. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 9.2. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 10.1. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 11.1. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 11.2. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 12.1. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 13.1. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 14.1. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 14.2. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 15.1. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 15.2. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 16.1. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 17.1. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 18.1. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 19.1. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 20.1. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 21.1. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 21.2. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 22.1. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 23.1. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 23.2. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 24.1. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 24.2. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 25.1. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 25.2. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 26.1. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 26.2. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 27.1. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 28.1. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 28.2. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 29.1. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 29.2. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Landscape And Company Profiles

• 30.1. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Landscape
• 30.2. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol Myers Squibb Company
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. AstraZeneca plc
• 31.5. Novartis AG
• 31.6. GlaxoSmithKline (GSK) plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. Moderna Inc.
• 31.11. BioNTech SE
• 31.12. Boehringer Ingelheim International GmbH
• 31.13. Cepheid Inc.
• 31.14. QIAGEN N.V.
• 31.15. Vir Biotechnology Inc.

32. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

34. Recent Developments In The Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

35. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market High Potential Countries, Segments and Strategies

• 35.1 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer